間充質(zhì)干細(xì)胞（mesenchymal stem cells，MSCs）是一種具有自我更新及多向分化潛能的干細(xì)胞。MSCs具有對多種腫瘤組織歸巢及定向遷移的特性，可以將其作為治療腫瘤藥物的載體，用來治療無法通過手術(shù)去除的腫瘤；同時，MSCs自身參與重塑腫瘤微環(huán)境，影響其侵襲、增殖和轉(zhuǎn)移等生物學(xué)行為，并且具有抗炎及損傷組織修復(fù)的能力。腫瘤壞死因子相關(guān)凋亡配體（TRAIL/Apo2L）作為誘導(dǎo)細(xì)胞凋亡的腫瘤壞死因子家族成員之一，可通過結(jié)合腫瘤細(xì)胞表面兩個特異性死亡受體（DR4、DR5），特異激活腫瘤細(xì)胞凋亡。TRAIL基因修飾的MSCs（TRAIL-MSCs）可定位至腫瘤組織并抑制原發(fā)腫瘤及轉(zhuǎn)移瘤的增殖、促進其凋亡，有望用于多種實體腫瘤及血液腫瘤的靶向治療。綜述了TRAIL-MSCs治療腫瘤的研究進展，并討論了TRAIL-MSCs聯(lián)合放化療對腫瘤的治療效果，為該療法在腫瘤治療領(lǐng)域的應(yīng)用提供理論依據(jù)。

Mesenchymal stem cells (MSCs) is one of adult stem cells with self-renewal and multi-differentiation potential. MSCs also possess other characteristics including homing and directional migration to a variety of tumor tissues, which can be used as a vehicle for anti-tumor drug to treat the tumors which cannot be removed by surgery. Meanwhile, MSCs participate in reshaping the tumor microenvironment, affecting their biological behaviors such as invasion, proliferation and metastasis, and have the ability to anti inflammation and repair damaged tissues, thus laying the foundation for development of tumor drug. Tumor necrosis factorrelated apoptosis ligand (TRAIL/Apo2L), as one of the tumor necrosis factor family, which can specifically induces tumor cells apoptosis by binding with two specific death receptors (DR4, DR5) on the surface of tumor cells. Studies have found that engineered mesenchymal stem cells over-expressing TRAIL (TRAIL-MSCs) migrate to tumor tissue to reduce the growth of primary cancers and metastases, and promote the tumor cells apoptosis. So TRAIL-MSCs can be used as to treat a variety of solid tumors and hematological tumors. This paper reviewed the research progress of TRAIL-MSCs in the treatment of tumor, and discussed the therapeutic effect of TRAIL-MSCs combined with radiotherapy and chemotherapy on tumor, providing theoretical basis for the application of trail-MSCs in the field of tumor treatment.

R979.1

北京市科技計劃課題（Z211100002521006）